8-K: Calidi Biotherapeutics Reports Q3 2025 Results, Advances RedTail Platform

Calidi Biotherapeutics announced its third quarter 2025 financial results and highlighted progress in its RedTail platform and CLD-401 development, alongside a successful $6.9 million public offering.

Summary

• Net loss for the third quarter ended September 30, 2025, was $5.2 million, compared to a net loss of $5.1 million for the same period in 2024.
• Net loss attributable to common stockholders increased to $10.8 million in Q3 2025, primarily due to a $5.7 million non-cash charge for deemed dividend on warrants.
• Net loss per share, basic and diluted, was $2.21 for Q3 2025, an improvement from $7.75 for the comparable period in 2024.
• Research and development expenses increased to $2.4 million in Q3 2025 from $2.2 million in Q3 2024.
• General and administrative expenses decreased to $2.7 million in Q3 2025 from $3.1 million in Q3 2024.
• Cash and restricted cash totaled $10.6 million as of September 30, 2025, compared to $9.8 million as of December 31, 2024.
• New preclinical data for CLD-401 was presented at the Society of Immunotherapy for Cancer (SITC), demonstrating protection from immune clearance and effective genetic medicine expression at tumor sites.
• A Scientific Advisory Board was established with internationally esteemed advisors to support CLD-401 development and advance the RedTail platform.
• The RedTail platform's functionality expanded to include programmable membranes and exploration of additional cell types and payloads.
• Raised $6.9 million in gross proceeds through an underwritten public offering, contributing to a total of $23.0 million in gross proceeds raised from all offerings in 2025.

Sentiment

Score: 7

Explanation: The company reported a higher net loss attributable to common stockholders due to a non-cash charge, but also showed a significant improvement in net loss per share. Operationally, there was strong progress with positive preclinical data, expansion of the RedTail platform, establishment of a Scientific Advisory Board, and a successful capital raise, which are all positive indicators for a clinical-stage biotech.

Positives

• Net loss per share significantly improved to $2.21 in Q3 2025 from $7.75 in Q3 2024.
• General and administrative expenses decreased to $2.7 million in Q3 2025 from $3.1 million in Q3 2024.
• Cash and restricted cash increased to $10.6 million as of September 30, 2025, from $9.8 million at December 31, 2024, strengthening the balance sheet.
• Successfully raised $6.9 million in gross proceeds from a public offering, extending the company's runway.
• Total gross proceeds raised in all offerings in 2025 reached $23.0 million.
• Positive preclinical data for CLD-401 presented at SITC, demonstrating protection from immune clearance and effective genetic medicine delivery to metastatic tumor sites.
• Established a Scientific Advisory Board with highly experienced members (Mace L. Rothenberg, Dmitriy Zamarin, John Wrangle, David T. Curiel).
• Expanded RedTail platform capabilities, including programmable membranes and exploration of new cell types and payloads, advancing virotherapy beyond oncology.

Negatives

• Net loss attributable to common stockholders increased to $10.8 million in Q3 2025 from $5.1 million in Q3 2024, primarily due to a $5.7 million non-cash charge for deemed dividend on warrants.
• Research and development expenses increased to $2.4 million in Q3 2025 from $2.2 million in Q3 2024.

Risks

• Risk that Calidi is not able to raise sufficient capital to support its current and anticipated clinical trials.
• Risk that early results of clinical trials do not necessarily predict final results and that one or more clinical outcomes may materially change following more comprehensive review of the data.
• Risk that Calidi may not receive FDA approval for some or all of its therapeutic candidates.
• Other risks and uncertainties are set forth in the 'Risk Factors and Cautionary Note Regarding Forward-Looking Statements' section in the Company's annual report on Form 10-K filed on March 31, 2025.

Future Outlook

CLD-401, the first lead candidate from the RedTail platform, is advancing to clinical trials. The RedTail platform continues to expand its functionality, exploring additional payloads and cell types beyond oncology. The company aims to deliver genetic medicines to distal sites of disease and effectively reach tumor sites, induce tumor lysis, and deliver potent gene therapies to metastatic locations. IND-enabling studies are underway for the lead RedTail candidate targeting non-small cell lung cancer, ovarian cancer, and other tumor types.

Management Comments

• "We are extremely excited about the continued progress at Calidi." Eric Poma, PhD, CEO of Calidi Biotherapeutics.
• "In our preclinical models, the RedTail platform continues to demonstrate its ability to potently and specifically deliver genetic payloads to metastatic tumor sites." Eric Poma, PhD, CEO of Calidi Biotherapeutics.
• "CLD-401, the first lead from our RedTail platform, is advancing to clinical trials, and Calidi has built a world-class scientific advisory board to aid those efforts." Eric Poma, PhD, CEO of Calidi Biotherapeutics.

Industry Context

Calidi Biotherapeutics operates in the highly competitive and innovative immuno-oncology and gene therapy space, focusing on virotherapy for cancer. The development of systemic delivery platforms like RedTail, designed to overcome immune clearance and target metastatic sites, represents a significant area of research and potential advancement in cancer treatment, aiming to improve upon localized dosing limitations. The establishment of a strong Scientific Advisory Board with leaders in oncology and virotherapy indicates a commitment to scientific rigor and strategic development in this rapidly evolving field.

Comparison to Industry Standards

• The company's focus on an engineered enveloped oncolytic virus for systemic delivery to metastatic sites positions it within a cutting-edge segment of virotherapy, aiming to address a key challenge of immune clearance that many non-enveloped or less protected viral therapies face.
• The preclinical data demonstrating protection from immune clearance and effective genetic medicine expression at tumor sites for CLD-401 suggests a potentially differentiated approach compared to other oncolytic virus therapies that may struggle with systemic administration efficacy.
• The formation of a Scientific Advisory Board with highly respected figures like Mace L. Rothenberg (former CMO of Pfizer) and leading experts in virotherapy and immunotherapy (Dmitriy Zamarin, John Wrangle, David T. Curiel) aligns with best practices for clinical-stage biotech companies seeking to validate and accelerate their development programs.

Management Changes

Corporate Governance

Related Party Transactions

• Related party accounts payable: $5 thousand as of September 30, 2025, compared to $2 thousand as of December 31, 2024.
• Related party accrued expenses and other current liabilities: $778 thousand as of September 30, 2025, compared to $480 thousand as of December 31, 2024.
• Related party term notes payable, net of discount, including accrued interest: $405 thousand as of September 30, 2025, compared to $2,702 thousand as of December 31, 2024.
• Related party bridge loan payable, including accrued interest: $0 as of September 30, 2025, compared to $223 thousand as of December 31, 2024.
• Related party other current liability: $0 as of September 30, 2025, compared to $638 thousand as of December 31, 2024.
• Related party warrant liability: $15 thousand as of September 30, 2025, compared to $9 thousand as of December 31, 2024.
• Interest expense related party: $10 thousand for Q3 2025, compared to $134 thousand for Q3 2024.
• Change in fair value of other liabilities and derivatives related party: $(7) thousand for Q3 2025, compared to $28 thousand for Q3 2024.

Stakeholder Impact

• Shareholders: The successful capital raise and extended runway provide financial stability, while positive preclinical data and advancement of the RedTail platform offer potential for future value creation. The increased net loss attributable to common stockholders due to a non-cash charge might be a short-term concern, but the improved net loss per share is positive.
• Employees: Continued progress in R&D and platform expansion suggests ongoing work and potential for growth within the company.
• Customers (future patients): Advancement of CLD-401 to clinical trials and expansion of the RedTail platform offer hope for new targeted therapies for various cancers, addressing unmet medical needs.

Next Steps

• CLD-401 is advancing to clinical trials.
• Continued expansion of RedTail platform capabilities, including exploring additional payloads and cell types outside of oncology.
• IND-enabling studies for the lead candidate from the RedTail platform, targeting non-small cell lung cancer, ovarian cancer, and other tumor types.
• Further development of protected virotherapies for intratumoral and localized administration for injectable cancer indications.

Key Dates

Recommendation

While the company shows strong operational progress with promising preclinical data, platform expansion, and a strengthened balance sheet from recent capital raises, it remains a clinical-stage biotechnology company. The increased net loss attributable to common stockholders due to a non-cash charge, despite an improved net loss per share, highlights the inherent financial volatility. The significant risks associated with clinical trials and FDA approval processes warrant a 'hold' recommendation for investors, suggesting monitoring progress closely rather than immediate aggressive buying or selling.

Keywords

Calidi Biotherapeutics, CLDI, biotechnology, immuno-oncology, RedTail platform, CLD-401, genetic medicines, oncolytic virus, cancer therapy, metastatic cancer, non-small cell lung cancer, ovarian cancer, SITC, financial results, Q3 2025, public offering, clinical-stage